Pharmacogenetics Home Collection Test Kit GetMyDNA recently launched a consumer-initiated Pharmacogenetics at-home test kit, which measures the body’s response to specific drugs. Currently, GetMyDNA checks for 88 different medications, as more guidance is received from the FDA, the medications checked will continue to grow. The GetMyDNA PGx Test Home Collection…

Research into the genetics of the metabolism of several drugs being used to treat COVID-19 suggests that variation in certain genes could influence how safe it is for individuals to be given these medications, both individually and in combination. Many of these drugs are not being used for the indication…

Since the completion of the Human Genome Project in 2003, the pharmacogenomics industry has experienced waxes and wanes in reaction to healthcare dynamics and technological advancements.[i] With the continued push towards personalized medicine, pharmacogenetics offers organizations a potential solution to fine-tune therapy by helping predict the patient’s response to a…

The Medical College of Wisconsin (MCW) has launched a new spin-off precision medicine company called RPRD (Right Person Right Drug) Diagnostics. RPRD is a comprehensive pharmacogenetics service for testing patients’ genomes with the aim of providing doctors with actionable information to enable precision medicine. The company, based in Milwaukee, will develop tests…

“An educated consumer is our best customer”—so said businessman and philanthropist Sy Syms. While Syms’ business was retail clothing, his slogan is broadly applicable. In fact, according to a recent survey by medical researchers, the clothiers’ wisdom can even guide physicians who hope to introduce their patients to the benefits…

Jonathan D. Grinstein, PhD, the North American Editor of Inside Precision Medicine, hosts a new series called Behind the Breakthroughs that features the people shaping the future of medicine. With each episode, Jonathan gives listeners access to their motivational tales and visions for this emerging, game-changing field. For the first…

Man’s fascination with space predates the first space shuttle launch or human footprints on the moon. Yet, sustaining human life in space requires creating a conducive environment and equipping the body with vital resources—such as pharmaceutical drugs—to help withstand the consequences of unique extraterrestrial stressors not experienced on Earth. The…

An analysis of a large trove of whole genome sequencing (WGS) data has shown that pharmacogenetic testing could be very valuable for most cancer patients taking even one of five common oncology drugs. The researchers found 62.7% of patients in the study had a genetic change that increased their risk…

A large-scale, collaborative study (PREPARE) has found that using a 12-gene pharmacogenetic (PGx) panel to preemptively screen all patients reduces adverse drug events significantly. The study also demonstrated feasibility of such testing, as it included 18 hospitals, nine community health centers, and 28 community pharmacies in seven European countries. As…

Sponsored content brought to you by Megan Martin   Megan Martin is a certified genetic counselor who joined the clinical services team in 2011. Over the years, her role has evolved into overseeing the clinical services team while providing guidance around process optimization, emerging technologies, genetic…

In a major milestone, the National Institutes of Health’s All of Us research program has begun returning health-related DNA results to its more than 155,000 participants. These results will tell participants if they have an increased risk for specific health conditions and how they might respond certain medications. This step is one…

Electronic health records (EHRs) – systems that control all hospital data – have been around since the early 1970s. One of the first, the Health Evaluation thru Logical Processing (HELP) system, was developed by medical informatics pioneer Homer Warner at LDS Hospital, now Intermountain Healthcare, in Salt Lake City, Utah.…

Josh Denny, CEO, All of Us IPM’s editor in chief Damian Doherty caught up with Josh Denny M.D., M.S., chief executive officer of the National Institutes of Health’s All of Us Research Program to get a current perspective on current progress and future goals. Josh has…

The Blue Care Network of Blue Cross Blue Shield of Michigan has launched a pilot program that will leverage the technology platform of pharmacogenomics company OneOme to help more accurately match patients with the right medications based on their molecular profile. Dubbed Blue Cross Personalized Medicine, the pilot will run…

Only five of the 126 drugs that were listed by both the FDA’s Table of Pharmacogenetic Associations and those listed by the Clinical Pharmacogenetics Implementation Consortium (CPIC) showed the same drug-gene associations and dosing implications. The differences point to one reason why pharmacogenomics (PGx) lags in adoption by physicians. “This…